CD274 and non-small cell lung carcinoma: Our previous study has already suggested that PD-L1 may be a marker to predict radiation resistance and treatment response to radiotherapy in NSCLC, and combined radiotherapy and anti-PD-L1 antibody could synergistically enhance antitumor effects in NSCLC (19).